Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks

The article reports multiple key FDA approvals for rare disease therapies, alongside strategic biopharma collaborations and acquisitions in the US market, highlighting sector volatility with trial successes and setbacks across multiple indications.

This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it.